Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 8/20 | 0.61 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.55 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.50 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.50 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6754596 | 0.89 | P2RY14 (0.61) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL16148484 | 0.89 | SLC28A1 (0.65) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL15515639 | 0.88 | P2RY2 (0.51) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL41269 | 0.85 | P2RY14 (0.55) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL366853 | 0.85 | P2RY14 (0.55) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL7611038 | 0.85 | P2RY14 (0.61) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL6028058 | 0.85 | P2RY14 (0.69) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL5964450 | 0.85 | P2RY14 (0.61) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL17065224 | 0.85 | P2RY14 (0.54) | P2RY14P2RY6P2RY2P2RY4SLC28A1 | |
| SCHEMBL7516112 | 0.84 | P2RY14 (0.60) | P2RY14P2RY6P2RY2P2RY4SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| EP-4298214-A1 | NUCLEIC ACID VECTORS AND METHODS OF USE | Intergalactic Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022182795-A1 | NUCLEIC ACID VECTORS AND METHODS OF USE | Intergalactic Therapeutics, Inc. (US) | 2022-09-01 | — | — | WO | disclosed |
| EP-3668520-A1 | MODIFIED MRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF | The Trustees Of The University Of Pennsylvania (US) | 2020-06-24 | — | — | EP | disclosed |
| US-20200140571-A1 | INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES | ATYR PHARMA INC (US) | 2020-05-07 | — | — | US | disclosed |
| WO-2019035066-A1 | MODIFIED MRNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| EP-3364980-A1 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070601-A1 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | P2RY14 2463/4885P2RY6 2935/4885P2RY2 3758/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | P2RY14 2463/4885P2RY6 2935/4885P2RY2 3758/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | P2RY14 2463/4885P2RY6 2935/4885P2RY2 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.